Shares of orphan drugmaker NPS Pharmaceuticals (NASDAQ: NPSP) are up more than 4% in intraday trading. The company, which gained Food and Drug Adminstration approval for its short bowel syndrome drug Gattex back in December, reported its first-quarter earnings and revealed the prescription numbers and sales of its drug launch. In the following video, health care analyst Max Macaluso discusses these details and three key takeaways from the company's first quarter.
Orphan drugmaker NPS Pharmaceuticals reveals the progress of its Gattex launch.
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo